TY - JOUR
T1 - Removal of endobronchial malignant mass by cryotherapy improved performance status to receive chemotherapy
AU - Fang, Yueh Fu
AU - Hsieh, Meng Heng
AU - Wang, Tsai Yu
AU - Lin, Horng Chyuan
AU - Yu, Chih Teng
AU - Chou, Chun Liang
AU - Lin, Shu Min
AU - Kuo, Chih Hsi
AU - Chung, Fu Tsai
N1 - Publisher Copyright:
© 2014 Yueh-Fu Fang et al.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Although malignant endobronchial mass (MEM) has poor prognosis, cryotherapy is reportedly a palliative treatment. Clinical data on postcryotherapy MEM patients in a university-affiliated hospital between 2007 and 2011 were evaluated. Survival curve with or without postcryotherapy chemotherapy and performance status (PS) improvement of these subjects were analyzed using the Kaplan-Meier method. There were 59 patients (42 males), with median age of 64 years (range, 51-76, and median performance status of 2 (interquartile range [IQR], 2-3). Postcryotherapy complications included minor bleeding (n=12) and need for multiple procedures (n=10), while outcomes were relief of symptoms (n=51), improved PS (n=45), and ability to receive chemotherapy (n=40). The survival of patients with chemotherapy postcryotherapy was longer than that of patients without such chemotherapy (median, 534 versus 106 days; log-rank test, P=0.007; hazard ratio, 0.25; 95% confidence interval, 0.10-0.69). The survival of patients with PS improvement postcryotherapy was longer than that of patients without PS improvement (median, 406 versus 106 days; log-rank test, P=0.02; hazard ratio, 0.28; 95% confidence interval, 0.10-0.81). Cryotherapy is a feasible treatment for MEM. With better PS after cryotherapy, further chemotherapy becomes possible for patients to improve survival when MEM caused dyspnea and poor PS.
AB - Although malignant endobronchial mass (MEM) has poor prognosis, cryotherapy is reportedly a palliative treatment. Clinical data on postcryotherapy MEM patients in a university-affiliated hospital between 2007 and 2011 were evaluated. Survival curve with or without postcryotherapy chemotherapy and performance status (PS) improvement of these subjects were analyzed using the Kaplan-Meier method. There were 59 patients (42 males), with median age of 64 years (range, 51-76, and median performance status of 2 (interquartile range [IQR], 2-3). Postcryotherapy complications included minor bleeding (n=12) and need for multiple procedures (n=10), while outcomes were relief of symptoms (n=51), improved PS (n=45), and ability to receive chemotherapy (n=40). The survival of patients with chemotherapy postcryotherapy was longer than that of patients without such chemotherapy (median, 534 versus 106 days; log-rank test, P=0.007; hazard ratio, 0.25; 95% confidence interval, 0.10-0.69). The survival of patients with PS improvement postcryotherapy was longer than that of patients without PS improvement (median, 406 versus 106 days; log-rank test, P=0.02; hazard ratio, 0.28; 95% confidence interval, 0.10-0.81). Cryotherapy is a feasible treatment for MEM. With better PS after cryotherapy, further chemotherapy becomes possible for patients to improve survival when MEM caused dyspnea and poor PS.
UR - http://www.scopus.com/inward/record.url?scp=84908346084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908346084&partnerID=8YFLogxK
U2 - 10.1155/2014/369739
DO - 10.1155/2014/369739
M3 - Article
C2 - 25383370
AN - SCOPUS:84908346084
SN - 2356-6140
VL - 2014
JO - Scientific World Journal
JF - Scientific World Journal
M1 - 369739
ER -